AR052264A1 - Compuesto de 1-sustituido-3-hidroxi-2-ciclopentil-[(hidrocarbil o hidroxicarbil) fenilo sustituido], su uso para la fabricacion de un medicamento y liquido oftalmicamente aceptable - Google Patents

Compuesto de 1-sustituido-3-hidroxi-2-ciclopentil-[(hidrocarbil o hidroxicarbil) fenilo sustituido], su uso para la fabricacion de un medicamento y liquido oftalmicamente aceptable

Info

Publication number
AR052264A1
AR052264A1 ARP050105163A ARP050105163A AR052264A1 AR 052264 A1 AR052264 A1 AR 052264A1 AR P050105163 A ARP050105163 A AR P050105163A AR P050105163 A ARP050105163 A AR P050105163A AR 052264 A1 AR052264 A1 AR 052264A1
Authority
AR
Argentina
Prior art keywords
substituted
hydrocarbyl
manufacture
liquid
offically
Prior art date
Application number
ARP050105163A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR052264A1 publication Critical patent/AR052264A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Compuesto de 1-sustituidos-3-hidroxi-2-ciclopentil-[(hidrocarbil o hidrocarbil)fenilo sustituido] que comprende la formula (1), o una sal farmacéuticamente aceptable o un profármaco de los mismos, donde una línea rayada representa la presencia o la ausencia de una union covalente, Y es un ácido carboxílico, ácido sulfonico, o ácido fosfonico; o una amida o éster de los mismos C0-12; o Y es un grupo hidroximetilo, o tetrazolilo funcional; A es -(CH2)6-, cis-CH2CH=CH-(CH2)3, o -CH2C:::C-(CH2)3-, donde 1 o 2 átomos de carbono pueden estar sustituidos con S u O; o A es (CH2)m-Ar-(CH2)o-, donde Ar es fenilo sustituido o no sustituido o heterarilo monocíclico, la suma de m y o es desde 1 hasta 4, y donde una CH2 puede estar sustituida con S u O; X es C=O, CHF, CF2, CHCl, o CHOH; donde si X es CHOH entonces OH está en la configuracion beta, R es un hidrocarbilo o una fraccion hidroxihidrocarbilo C1-12; D es independientemente una fraccion que comprende desde 1 hasta 6 átomos de no hidrogeno; y n es un entero desde 0 hasta 4. uso de dichos compuestos para la fabricacion de un medicamento para el tratamiento del glaucoma o la reduccion de la presion intraocular. Líquido oftálmicamente aceptable que comprende dichos compuestos. Compuesto que comprende un agonista selectivo de una prostaglandina EP2, donde la cadena omega comprende un fenilo sustituido y al menos un sustituyente consiste de hidrocarbilo o hidroxihidrocarbilo no lineal.
ARP050105163A 2004-12-10 2005-12-09 Compuesto de 1-sustituido-3-hidroxi-2-ciclopentil-[(hidrocarbil o hidroxicarbil) fenilo sustituido], su uso para la fabricacion de un medicamento y liquido oftalmicamente aceptable AR052264A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/009,298 US7091231B2 (en) 2004-12-10 2004-12-10 12-Aryl prostaglandin analogs

Publications (1)

Publication Number Publication Date
AR052264A1 true AR052264A1 (es) 2007-03-07

Family

ID=36578246

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105163A AR052264A1 (es) 2004-12-10 2005-12-09 Compuesto de 1-sustituido-3-hidroxi-2-ciclopentil-[(hidrocarbil o hidroxicarbil) fenilo sustituido], su uso para la fabricacion de un medicamento y liquido oftalmicamente aceptable

Country Status (21)

Country Link
US (3) US7091231B2 (es)
EP (1) EP1819670B1 (es)
JP (1) JP5342142B2 (es)
KR (1) KR101367553B1 (es)
CN (1) CN101107225B (es)
AR (1) AR052264A1 (es)
AU (1) AU2005314000B2 (es)
BR (1) BRPI0518642A2 (es)
CA (1) CA2589864C (es)
DK (1) DK1819670T3 (es)
ES (1) ES2394838T3 (es)
HK (1) HK1114832A1 (es)
IL (1) IL183360A (es)
MX (1) MX2007006690A (es)
NO (1) NO20072662L (es)
NZ (1) NZ555352A (es)
PL (1) PL216197B1 (es)
RU (1) RU2439055C2 (es)
TW (1) TWI392666B (es)
WO (1) WO2006063179A1 (es)
ZA (1) ZA200704087B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7674786B2 (en) * 2005-05-06 2010-03-09 Allergan, Inc. Therapeutic β-lactams
US8039507B2 (en) * 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP3069752B1 (en) 2006-03-29 2018-03-28 Dignity Health Microburst electrical stimulation of cranial nerves for the treatment of medical conditions
US20090016981A1 (en) * 2006-05-03 2009-01-15 Allergan, Inc. Therapeutic compounds
US7491844B2 (en) * 2006-05-04 2009-02-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US7476755B2 (en) 2006-05-04 2009-01-13 Allergan, Inc. Therapeutic compounds
US7547727B2 (en) * 2006-05-22 2009-06-16 Allergan, Inc. Therapeutic cyclopentane derivatives
EP2057128A2 (en) * 2006-09-01 2009-05-13 Allergan, Inc. Therapeutic substituted hydantoins and related compounds
US7429671B2 (en) * 2006-12-06 2008-09-30 Air Products And Chemicals, Inc. Process for the fluorination of boron hydrides
BRPI0806716A2 (pt) * 2007-01-22 2011-09-06 Allergan Inc arilciclopentenos substituìdos como agentes terapêuticos
EP2114913B1 (en) * 2007-01-22 2011-06-01 Allergan, Inc. Thiophene derivatives useful as ocular hypotensive agents
CA2676252A1 (en) * 2007-01-25 2008-07-31 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US9365485B2 (en) 2007-01-25 2016-06-14 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US8377984B2 (en) * 2008-01-29 2013-02-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
BRPI0808377B8 (pt) * 2007-01-31 2021-05-25 Allergan Inc composto, composição e uso de um composto
EP2118094B1 (en) * 2007-02-15 2013-04-17 Allergan, Inc. Gamma-lactams for the treatment of glaucoma or elevated intraocular pressure
US7589213B2 (en) * 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
EP2155733B1 (en) * 2007-05-23 2012-09-26 Allergan, Inc. Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure
BRPI0813176A2 (pt) * 2007-06-15 2014-12-30 Mission Pharma Co Moléculas e composições par ainibir fator edema e adenilil ciclase
US7662850B2 (en) * 2007-07-13 2010-02-16 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US7947732B2 (en) 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US20090062361A1 (en) * 2007-08-30 2009-03-05 Allergan, Inc. Therapeutic hydantoins
CN102977048A (zh) * 2007-11-09 2013-03-20 阿勒根公司 具有前列腺素活性的取代环戊烷
CA2706879A1 (en) 2007-11-29 2009-06-11 Robert M. Burk Substituted cyclopentanes having prostaglandin activity
US8063033B2 (en) 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US7956051B2 (en) * 2008-01-24 2011-06-07 Allergan, Inc. Therapeutic amides and related compounds
US8455547B2 (en) * 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
US8633310B2 (en) * 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US8440819B2 (en) * 2008-02-22 2013-05-14 Allergan, Inc. Therapeutic substituted beta-lactams
US8487091B2 (en) * 2008-03-04 2013-07-16 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
US7964596B2 (en) * 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
US20090233921A1 (en) * 2008-03-11 2009-09-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US7960379B2 (en) * 2008-03-14 2011-06-14 Allergan, Inc. Therapeutic compounds
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US8198318B2 (en) * 2008-03-18 2012-06-12 Allergen, Inc. Therapeutic amides
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
US7956055B2 (en) * 2008-03-25 2011-06-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2009236356A1 (en) * 2008-04-16 2009-10-22 Allergan, Inc. Combination therapy for glaucoma
US7964634B2 (en) * 2008-04-24 2011-06-21 Allergan, Inc. Therapeutic compounds
AU2009239372B2 (en) * 2008-04-24 2013-09-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2009131977A1 (en) 2008-04-24 2009-10-29 Allergan, Inc. Therapeutic compounds
CA2722403C (en) * 2008-04-24 2017-03-07 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
ES2381435T3 (es) * 2008-04-24 2012-05-28 Allergan, Inc. Derivados de tiofeno útiles como agentes hipotensores oculares
WO2009132085A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Substituted arylcyclopentenes as prostaglandin ep2 agonists
EP2285782A2 (en) * 2008-05-09 2011-02-23 Allergan, Inc. Therapeutic n-aryl or n-heteroaryl pyrazolidine and pyrazolidinone derivatives
AU2009244513B2 (en) * 2008-05-09 2014-04-10 Allergan, Inc. Therapeutic cyclopentane derivatives
JP2011519939A (ja) * 2008-05-09 2011-07-14 アラーガン インコーポレイテッド 治療用化合物
WO2009137411A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
US8569349B2 (en) * 2008-05-09 2013-10-29 Allergan, Inc. Therapeutic compounds
CA2723894A1 (en) 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic substituted hydantoins, and related compounds
AU2009249388B2 (en) * 2008-05-20 2014-04-03 Allergan, Inc. Therapeutic lactams
EP2300412A1 (en) * 2008-05-27 2011-03-30 Allergan, Inc. Prostaglandin produgs as hypotensive agents
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
US9090584B2 (en) 2010-01-26 2015-07-28 Allergan, Inc. Therapeutic agents for treatment of ocular hypertension
US8299068B2 (en) 2010-01-29 2012-10-30 Allergan, Inc. Therapeutically active cyclopentanes
ES2711425T3 (es) * 2012-08-27 2019-05-03 Allergan Inc Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos
WO2014194209A1 (en) 2013-05-31 2014-12-04 Allergan, Inc. Substituted cyclopentenes as therapeutic agents
US10100028B2 (en) 2013-09-30 2018-10-16 Patheon Api Services Inc. Synthesis routes for prostaglandins and prostaglandin intermediates using metathesis
WO2016054596A1 (en) 2014-10-02 2016-04-07 Allergan, Inc. Ester prodrugs of gamma-lactams and their use
KR102069205B1 (ko) * 2017-08-09 2020-01-22 연성정밀화학(주) 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066834A (en) * 1974-01-24 1978-01-03 Miles Laboratories, Inc. Cycloalkenyl analogues of prostaglandins E
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4168452A (en) * 1976-06-10 1979-09-18 Zenith Radio Corporation Tetrode section for a unitized, three-beam electron gun having an extended field main focus lens
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
DE3100578A1 (de) * 1980-01-25 1982-02-11 Farmitalia Carlo Erba S.p.A., 20159 Milano Isoxazolyl- und isoxazolinyl-prostaglandine, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische und veterinaermedizinische mittel
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE4330177A1 (de) * 1993-08-31 1995-03-02 Schering Ag Neue 9-Chlor-prostaglandin-derivate
US5462968A (en) * 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5698598A (en) 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
US6090874A (en) * 1995-12-13 2000-07-18 Zeon Chemicals L.P. High clarity carboxylated nitrile rubber
JP3162668B2 (ja) * 1997-02-04 2001-05-08 小野薬品工業株式会社 ω−シクロアルキル−プロスタグランジンＥ２誘導体
US6531485B2 (en) * 1997-06-23 2003-03-11 Pfizer Inc. Prostaglandin agonists
US6090847A (en) * 1997-11-21 2000-07-18 Allergan Sales, Inc. EP2 -receptor agonists as neuroprotective agents for the eye
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
JP2001527063A (ja) * 1998-12-24 2001-12-25 小野薬品工業株式会社 ω−シクロアルキル−プロスタグランジンＥ２誘導体
CA2416906A1 (en) * 2000-08-09 2002-02-14 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis of (r)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-h-imidazo[1,2-a]imidazol-2-one
WO2003040126A1 (en) * 2001-11-05 2003-05-15 Allergan, Inc. φ-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS
US6747037B1 (en) * 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
GB0329620D0 (en) 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
US7476747B2 (en) * 2005-03-10 2009-01-13 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2007109578A2 (en) * 2006-03-20 2007-09-27 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists

Also Published As

Publication number Publication date
PL216197B1 (pl) 2014-03-31
ZA200704087B (en) 2008-09-25
US20060148894A1 (en) 2006-07-06
ES2394838T3 (es) 2013-02-06
CN101107225B (zh) 2012-11-28
HK1114832A1 (en) 2008-11-14
TW200633966A (en) 2006-10-01
TWI392666B (zh) 2013-04-11
US7091231B2 (en) 2006-08-15
EP1819670B1 (en) 2012-08-08
NO20072662L (no) 2007-09-04
DK1819670T3 (da) 2012-09-17
US20100317872A1 (en) 2010-12-16
CN101107225A (zh) 2008-01-16
PL383422A1 (pl) 2008-03-17
JP5342142B2 (ja) 2013-11-13
RU2007120520A (ru) 2009-01-20
JP2008523088A (ja) 2008-07-03
AU2005314000A1 (en) 2006-06-15
US8044092B2 (en) 2011-10-25
IL183360A0 (en) 2007-09-20
CA2589864C (en) 2015-02-03
US20060205800A1 (en) 2006-09-14
EP1819670A1 (en) 2007-08-22
AU2005314000B2 (en) 2012-06-14
KR101367553B1 (ko) 2014-03-14
KR20070086001A (ko) 2007-08-27
CA2589864A1 (en) 2006-06-15
NZ555352A (en) 2011-01-28
RU2439055C2 (ru) 2012-01-10
MX2007006690A (es) 2007-08-14
WO2006063179A1 (en) 2006-06-15
US7799821B2 (en) 2010-09-21
BRPI0518642A2 (pt) 2008-12-02
IL183360A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
AR052264A1 (es) Compuesto de 1-sustituido-3-hidroxi-2-ciclopentil-[(hidrocarbil o hidroxicarbil) fenilo sustituido], su uso para la fabricacion de un medicamento y liquido oftalmicamente aceptable
AR052876A1 (es) Uso de compuestos de ciclopentano y ciclopentanona substituidos para la fabricacion de un medicamento para tratamiento del glaucoma o de la hipertension ocular, composicion y compuestos correspondientes
CO5640076A2 (es) Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento
ES2181320T3 (es) Procedimiento para la produccion de formas solidas de dosificacion.
ES2551307T3 (es) Composición de inhalación que contiene aclidinio para tratamiento de enfermedad pulmonar obstructiva crónica
ES2674719T3 (es) Terapias para neoplasias hematológicas
WO2006047476A3 (en) Therapeutic and delivery methods of prostaglandin ep4 agonists
KR102537043B1 (ko) 조합 치료요법용 약학 조성물
CO6160236A2 (es) Inhibidor de quinasa
AR050463A1 (es) Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer.
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
EP0448274A2 (en) Use of a thromboxane A2 receptor antagonist for the manufacture of a medicament for the treatment of ulcerative gastrointestinal conditions
RU2003136759A (ru) Пролекарства ингибиторов дипептидилпептидазы iv
AR074391A1 (es) Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral
AR059575A1 (es) Metodo para el tratamiento de enfermedades inflamatorias
RU2014149337A (ru) Аналоги этомидата с улучшенными фармакокинетическими и фармакодинамическими свойствами
CN111902394B (zh) 与特异性促炎症消退介质的盐有关的组合物和方法
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
RU2010138650A (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
US20110082120A1 (en) Substituted thioacetic acid salicylate derivatives and their uses
Takeuchi et al. COX inhibition and NSAID-induced gastric damage-roles in various pathogenic events
RU2006120426A (ru) Замещенные триазолы в качестве блокаторов натриевых каналов
CO5560585A2 (es) Formulacion farmaceutica para administracion intramuscular de fulvestrant
US20100022646A1 (en) method of neutralising organoboronates with acids

Legal Events

Date Code Title Description
FA Abandonment or withdrawal